Brenig Therapeutics develops therapies for neurodegenerative disorders.
Brenig Therapeutics has raised $65.0M in total funding. The most recent round was Series A. The last funding was announced in July 2024.
Brenig Therapeutics's investors include New Enterprise Associates, OrbiMed, BioGeneration Ventures, Torrey Pines Investment.
Brenig Therapeutics is headquartered in Dover, United States.
Brenig Therapeutics develops therapies for neurodegenerative disorders.
Brenig Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Brenig Therapeutics — Funding & Investors." VCBacked, July 24, 2024, https://www.vcbacked.co/company/brenig-therapeutics. Accessed July 20, 2026.
VCBacked. (2024). Brenig Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/brenig-therapeutics
{{cite web |title=Brenig Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/brenig-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated